Objectives: To evaluate the risks of depression and all-cause mortality, healthcare utilisation costs and treatment adherence in congenital adrenal hyperplasia (CAH) in the United Kingdom. Design and methods: A retrospective, matched-cohort study using UK primary-care data from the Clinical Practice Research Datalink linked to hospital and death certification data. Patients diagnosed with CAH and having ≥1 corticosteroid prescription were matched 1:10 to reference subjects. Risk of death and lifetime prevalence of depression were compared using Cox regression models. Direct financial costs were estimated for healthcare contacts.
Introduction
Congenital adrenal hyperplasia (CAH) comprises a group of genetic disorders in which cortisol synthesis is disrupted (1) , leading to deficiencies of cortisol and, potentially, aldosterone with consequent increased production of androgens. Clinical manifestations of classical CAH include acute, life-threatening adrenal crises and androgen excess, resulting in genital ambiguity and hirsutism in females, precocious puberty, infertility and compromised quality of life in both men and women (2, 3) . A milder, non-classical (not salt-wasting) form of the disease can produce symptoms such as irregular menstrual periods and fertility problems later in life, but many patients with non-classical CAH are asymptomatic and most are not treated with corticosteroids; the focus of this paper is, therefore, classical CAH.
The British Paediatric Surveillance Unit has reported that CAH affects approximately 1:18 000 live-born infants in Great Britain (4) . Treatment of CAH since the 1950s has taken the form of lifelong replacement therapy with glucocorticoids and, where needed, mineralocorticoids, although no licensed paediatric dose formulation exists for neonates and infants, and there are concerns that the physiological circadian rhythm of cortisol is not successfully mimicked by existing products (5, 6) . Data from long-term registries have suggested that CAH is associated with excess mortality and morbidity risk (3) , and this may relate to glucocorticoid replacement (2, 7) .
In this retrospective matched-cohort study, we evaluated the burden of CAH in a UK population by analysing the risk of depression and all-cause mortality, and estimating healthcare use, costs and adherence to oral corticosteroid therapy.
Patients and methods
Data were from: the Clinical Practice Research Datalink (CPRD) primary-care data set and linked additional data sets (where eligible): death-certificate data from the Office for National Statistics (ONS) and inpatient and outpatient data from the Hospital Episode Statistics (HES) for England (8, 9, 10) . Approval for this study was granted by the CPRD Independent Scientific Advisory Committee (reference number 15_203).
CPRD is an ongoing database of pseudonymised data collected in a non-interventional way from participating primary-care practices throughout the United Kingdom. At January 2015, it contained more than 13 million research quality patients registered at 684 practices. For more than 7 million patients (54%) registered with participating English practices, their records can be linked with other data sources, notably HES (containing details of every hospital admission and outpatient appointment in England) and ONS mortality data (the legal repository for the notification of deaths in England and Wales).
The study population were patients with a CAH diagnosis recorded by Read Code (CPRD) or ICD-10 code (HES), as listed in Supplementary Table 1 (see section on supplementary data given at the end of this article), and drawn from patients flagged by CPRD as having acceptable research quality. To substantiate patients' CAH status, we required patients to have at least one prescription for a corticosteroid. Where a patient's records included a conflicting diagnosis, the record was assessed by an endocrinologist (author R J M R) to confirm the CAH diagnosis. The date of the patient's first CAH record was the earlier of their first CAH diagnostic record or their first corticosteroid prescription. The patient's index date, equating to start of follow-up, was the latest of the patient's first CAH record, their registration date or their general practice's up-to-standard date (a CPRD research quality indicator). End of follow-up was the earliest of the patient's death date, transfer from the practice or the practice's last data-collection date. The entire CAH study population participated in the comparative analysis of depression (if matched) and analysis of therapy adherence. In the comparative analyses of all-cause mortality and healthcare use, we considered patients eligible to participate in the appropriate linkage scheme and having index dates within the coverage periods of the linked datasets. In analyses by age group, patients were included if they became eligible for inclusion in that age group at any time in their follow-up period; patients were then observed while their age group interval was concurrent with the data follow-up period. For comparative analyses, patients with CAH were matched with reference (control) patients randomly selected from CPRD patients having no record of CAH, adrenal crisis or other adrenal insufficiency at any time in their primary-care and linked HES records. CAH patients were matched 1:10 with control patients on year of birth, gender, general practice, registration at case index date and eligibility for linkage to the HES and death-certificate data sets. The last of these criteria, linkage eligibility, was necessary in order to create comparable matched cohorts for analyses based on the linked data sets. Control patients inherited the index date of their matched CAH patient.
Study endpoints

Death and depression
Death was determined from death certification and depression by Read Code in CPRD, by ICD-10 code in HES inpatient data, or by the prescription of antidepressants. A sensitivity analysis considered only those depression outcomes identified by both diagnostic (Read or ICD-10) code and at least one antidepressant prescription.
Lifetime prevalence of depression rather than incident occurrence was compared because the clustering of apparently incident diagnoses around registration date might have led to ascertainment bias in the CAH study arm. Depression was identified not only from ongoing records but also from patients' clinical histories dating from before the start of data follow-up (from records transferred or transcribed from other general practices or from records entered before the practice's up-to-standard date or in the course of the patient's previous period of registration at the practice).
Treatment adherence
Medical possession ratio (MPR) was used as a proxy for CAH patients' adherence to oral corticosteroid medications as prescribed. This standard measure was calculated as the total days' supply prescribed over an observation period divided by the duration of that observation period (11) . An MPR <80% is considered to indicate poor compliance (12) .
Healthcare resource use and costs
Primary-care contacts were identified from CPRD's consultation table, and inpatient admissions and outpatient attendances from the linked HES inpatient and outpatient data sets, respectively. Resource use and costs were analysed in two different subsets of the data: primarycare costs in all CAH and control patients regardless of linkage eligibility, followed from start (index date) to end of CPRD data follow-up; and combined primary-and secondary-care costs in linkage-eligible CAH patients and their controls, followed from the later of their index date and the start of HES follow-up to the end of combined CPRD and HES follow-up. Given that a proportion of identified patients could not be observed in the period in which CAH first presented, sensitivity analyses were carried out, selecting only those CAH patients (and their controls) who had data follow-up that included their first record of CAH or closely followed it (within 365 days of first CAH and of patient's year of birth).
Each primary-care consultation was classified by consultation type (e.g. clinic, surgery, home visit) and staff role (e.g. doctor, practice nurse) and then assigned an average cost as listed in the Unit Costs of Health and Social Care 2013/2014 from the Personal Social Services Research Unit (PSSRU) (13) . Where only the average cost per hour was published, the GP Workload Survey (14) was consulted in order to determine the average length of the consultation, from which the average cost for that consultation could be calculated. Each inpatient admission was allocated a Healthcare Resource Group (HRG) using local payment grouper software (15) , thereby aggregating spells of patient care into categories that are homogenous in terms of resource use. The allocated HRG was then linked to the 2013/2014 National Tariff (16) and the relevant cost applied depending upon the nature of the spell. Additional costs relating to excess length of stay, as defined by the National Tariff, were also allocated. Where no cost could be allocated, mean costs were assigned by spell type: elective, emergency or day. Where possible, the main specialty recorded for each outpatient appointment was used to assign a cost from the 2013/2014 National Tariff (16) . If a cost could not be applied by main specialty, treatment specialty was used instead. Different costs were applied to first and follow-up appointments. Where a specialty was not listed in the tariff, costs were applied from the 2013/14 NHS Reference Costs (17) . The same costs were applied to appointments that were not attended.
Statistical methods
Baseline characteristics of CAH patients and their controls at index date (start of data follow-up) were aggregated and compared using the independent t-test or Mann-Whitney U test depending upon their distribution. Categorical variables were compared using the chi-square test. For the survival analysis, Kaplan-Meier curves stratified by the study arm were produced. Time from index date to death was evaluated using Cox proportional hazards modelling, with adjustments for age, sex, Charlson comorbidity index (18) and index year (omitting sex where results were presented by gender). The proportional hazards assumption was tested by examining the Pearson correlation between Schoenfeld residuals and the rank of survival time for cases that had progressed to death. Lifetime prevalence of depression was compared between study arms by chi-square test. Rates and costs of healthservice use per person year were calculated and compared between CAH patients and their matched controls using the Mann-Whitney U test. MPR in patients with CAH were presented as summary statistics in tabular form. The point prevalence of corticosteroid-treated CAH patients in the CPRD population was calculated for 30 June 2013 as the number of CAH patients with an index date ≤30 June 2013 and an end of follow-up ≥30 June 2013, divided by the CPRD population with a registered status on that date and presented with 95% Wilson score confidence intervals.
Results
We identified 1188 research quality patients having at least one diagnostic code for CAH in the CPRD or linked HES inpatient data. Of these, 67 were excluded because their first CAH diagnostic record was dated after the end of CPRD follow-up; a further 41 were excluded because they shared a linked identity in HES with another patient; and three with conflicting adrenal diagnoses were excluded as ; P < 0.001), respectively. The smoking profiles of CAH and control patients were similar, but a higher proportion of CAH patients described themselves as 'ex-drinkers' compared with control patients: 4% vs 1% overall (P = 0.001), 3% vs 1% in female patients (P = 0.010) and 6% vs 1% in male patients (P = 0.037), respectively. Thirty-nine (7%) CAH patients had records of adrenal crisis, 17 (44%) were male, 22 (56%) female. Nine CAH patients had ≥1 adrenal crisis while aged 6 years or younger, 11 aged 7-17 years, 10 aged 18-25 years and 12 aged 26 years or older. There were no records of adrenal crisis in the control patients.
Baseline characteristics
All-cause mortality
270 CAH patients, matched with 2700 control patients, were eligible for inclusion in the comparison of mortality risk. Mean (s.d.) age at start of mortality follow-up was 23.3 (19.7) years in each cohort, with a mean (s.d.) follow-up of 5.3 (4.3) years in CAH patients and 5.8 (4.5) years in control patients. There were 17 deaths amongst the 270 eligible CAH patients, corresponding to a crude mortality rate of 11.9 deaths per 1000 person-years (Table 2 ). Amongst the 2700 eligible control patients, there were 41 deaths, corresponding to 2.6 deaths per 1000 person-years. Kaplan-Meier curves for female, male and all patients and stratified by study arm are shown in Fig. 1 
Depression
The lifetime prevalence of depression was 33.5% in CAH patients vs 26.1% in control patients, a prevalence ratio of 1.28 (95% CI 1.13-1.45, Table 3 ). In a sensitivity analysis in which depression was identified by the presence of both a diagnostic code and an antidepressant prescription, the lifetime prevalence decreased in both Table 2 ).
Healthcare costs
Total costs are presented by age group in Table 4 , with stratified primary and secondary healthcare costs presented in Supplementary Tables 3A, B, C and D and  healthcare resource use in Supplementary Tables 4A, B , C and D. Mean (s.d.) annual total healthcare costs were higher for patients with CAH than for controls across all age groups: £7038 (£14 846) vs £2879 (£13 972) in those (Table 4) . Mean total annual costs were highest in CAH patients aged 0-6 years due to frequent inpatient admissions, especially in female patients (Table 4 and Supplementary Tables 3A  and 4A ) and lowest in young adults aged 18-40 (Table 4  and Supplementary Tables 3C and 4C ). Supplementary  Tables 5 and 6 detail primary and secondary healthcare resource use and costs, respectively, for CAH and control patients irrespective of age. Both resource use and mean annual total primary and secondary healthcare costs were significantly higher for patients with CAH vs control patients. Resource use and costs remained significantly higher in the sensitivity analysis in which CAH patients were observable from, or shortly after, their first CAH record (Supplementary Tables 7 and 8 ) and when a larger subset of the study population was analysed, comprising CAH and control patients regardless of linkage eligibility (Supplementary Tables 9 and 10 ). 
Treatment adherence
Discussion
This retrospective, observational study showed that CAH patients had a higher risk of mortality and depression, increased healthcare utilisation with accompanying increased costs and poor medication adherence. In our study, the adjusted risk of death was more than five times higher in patients with CAH than in a reference group of patients having no history of adrenal insufficiency, with the risk being higher in males than in females. A similar trend was observed in a Swedish setting (3), although the excess risk in patients with CAH (a hazard ratio of 2.3) was lower than that observed here and the difference in risk between genders was reversed. Multiple factors may have affected the results in the two countries, such as Sweden's nationwide neonatal screening programme for CAH, introduced in 1986, and differences in sample sizes, study design and the availability of neonatal data.
Excess deaths in CAH have been attributed to saltwasting adrenal crises, particularly in male infants, in whom the external signs of CAH (ambiguous genitalia) are less apparent than in female infants (3) . This preponderance of females identified with CAH in many studies, as in ours, might, therefore, be due to higher numbers of male infants dying, especially in the absence of neonatal screening (19) . In our study, however, there was an increased mortality in men and women in middle age, with the mean age at death of CAH patients being 54.8 years, 18 years earlier than in the matched reference group. Mean ages at death were similar in male and female patients with CAH, at 53.3 years vs 55.8 years, respectively, and there were no deaths amongst CAH patients under the age of 13 years. It should be noted, however, that neonatal deaths occurring before the infant could be registered at a primary-care practice would not have been captured in our data source. The mean age of death in the control group, at 72.8 years, was younger than might be expected from the background population. However, the CAH and control cohorts were relatively young, with mean age at the start of follow-up 23.3 years and mean follow-up 5 years, therefore, one would expect the deaths that could be captured to be those occurring at a younger age. Depression in patients with CAH was 30% higher than in controls, increasing to nearly 40% in a sensitivity analysis of pharmaceutically treated depression. Overall and by age group, the lifetime prevalences of both depression and pharmaceutically treated depression were higher in women with CAH. It has been suggested that the experiences of women affected by virilisation and corrective surgery for ambiguous genitalia may have lasting adverse effects on their quality of life (20, 21, 22) . Previous studies of mental health in women with CAH have reported varying outcomes, with one UK study reporting scores for psychological outcomes within normal ranges (23) and another, again in UK patients, reporting increased scores for depression in females with classic CAH but not in those with the non-classic form (2) . A matched control study in 70 Danish women with disorders of sex development, of whom 33 had CAH, found that CAH was associated with impaired quality of life and greater affective distress (24) . In our study, the prevalence of depression varied according to age and gender: the lifetime prevalence of depression was twice as high in children and nearly 70% higher in men of 41 years and older. Arlt and colleagues (2) reported increased scores for depression in male patients with classic CAH, compared with matched controls, while Falhammar and colleagues (25) reported increased psychiatric disorders in male Swedish patients with CAH, with older patients born before the introduction of neonatal screening in 1986 being most affected. One observation from our study that may be related to these findings was that more patients with CAH than controls described themselves as 'ex-drinkers'. Further work on associations between alcohol and CAH would be interesting. It is also worth considering that the burden of CAH falls not only on the patient but also on their family: the parents of young children with CAH take on the role of primary caregiver, managing complex treatment regimens and the frequent, intercurrent childhood illnesses that could lead to adrenal crisis. Parents interviewed about their experiences have reported stress, anxiety and disruption to their sleep and working lives (26) . Annual mean healthcare costs were greater for CAH patients than their controls and greater for children than for adults. Mean costs in female CAH patients aged 0-6 years, at £8147 per year, were largely attributable to inpatient admissions and were nearly nine times higher than in age-matched controls. It is important to note that, because this study was based on primarycare data, the early neonatal period, the time when CAH characteristically presents, often as adrenal crisis, will not have been fully captured. Annual mean costs were lowest in the younger adult age group (aged 18-40 years); in female patients, these remained significantly higher than those in controls, but in male patients the position was reversed, with costs being significantly lower than those in control patients. In older adults (aged 41 years and over), annual mean costs were increased in absolute terms and were again higher than those in control patients in all comparisons. In this age group, for the first time, mean costs in male patients with CAH were higher than those in female patients. It is interesting to speculate whether this might be related to decreased healthcare utilisation for menstruation disorders or fertility as female patients approach menopause or increased consultations in males, perhaps associated with cardiovascular risk (27) , but this needs to be investigated further. Only one other study, to our knowledge, has examined healthcare resource use and costs in patients with CAH, but the results were similar. This matched-cohort study (28) investigated healthcare burden associated with adrenal insufficiency in a US claims database and found that healthcare costs in the CAH cohort (n = 551) were significantly higher than in matched, non-exposed patients, with mean expenditure (including pharmacy costs) in the year following index diagnosis of $7677 vs $4203, respectively.
We found children to be more compliant with their medication than adults. This was expected, as their parents would typically take responsibility for administering medication and children generally receive closer medical follow-up to monitor growth and development. However, even in the two paediatric age groups, just under 20% of patients were identified as non-compliant. Deficiencies in the transition of CAH patients from paediatric to adult care are well recognised (29) and are confirmed in this study, with a third of adult patients being non-compliant based on a medical possession ratio <80%. Noncompliance with glucocorticoid replacement therapy in CAH patients, with associated androgen excess, has been linked to reduced final adult height, impaired fertility and brain abnormalities in magnetic resonance imaging (30, 31, 32) . In addition, analysis of a US claims database has demonstrated that healthcare expenditure is reduced in patients with adrenal insufficiency who are compliant with glucocorticoid replacement therapy (28) .
This study, in common with other analyses of realworld data sources, has a number of limitations. Even though the validity of medical diagnoses in CPRD (and its precursor, the General Practice Research Database) has been confirmed in several studies (33, 34) , the use of a primary-care data set can be seen as a study limitation, given that the diagnosis and initial care for CAH will have been delivered in a hospital setting. Our requirement that all CAH patients should have at least one record of corticosteroid prescription in order to substantiate status led to the exclusion of approximately 45% of patients, which is suggestive that at least a proportion of the excluded patients received their medication in secondary care, which would not be recorded in the database. Due to the complexities of CAH, the primary-care practitioner in the United Kingdom is unlikely to have been responsible for its diagnosis or its initial treatment, which will have been undertaken instead by secondary-care specialists. However, Adrenal crisis, especially in the absence of neonatal screening, is a relatively common presentation in males with classic CAH, typically occurring at two weeks or younger (35) . However, costs relating to these periods of critical care will have been under-represented in our study because the patient will not usually be registered with a CPRD practice at that age and because specific costs for neonatal and paediatric critical care are not included in the UK National Tariff, which was our source for costing inpatient admissions. An indicative cost of £1000 per bed day is, however, listed in the 2013/2014 NHS Reference Costs for paediatric critical care not requiring ventilation (17) .
The prevalence for our studied patients in the data set was 1:17 135, which is slightly higher than that implied by the incidence of 1:18 000 live births reported by the British Paediatric Surveillance Unit (4). Nevertheless, it is apparent that the healthcare burden of CAH in the United Kingdom remains to be fully elucidated.
A potential weakness of our study lies in our use of non-exposed control patients instead of patients with other chronic inborn diseases in our analyses of healthcare use and costs. Over 98% of the UK population is registered with a primary-care practice (36) . Therefore, a nonexposed control population derived from a source such as CPRD, particularly one in which patients are matched by age to a relatively young cohort of exposed patients, will almost certainly be largely composed of healthy individuals. Indeed, the Charlson comorbidity index generated for our adult control population (based on 19 clinical conditions, including diabetes and malignant tumour) has an interquartile range of zero, suggesting low comorbidity. A marked difference in costs between the CAH and control population is not unexpected therefore. However, for healthcare organizations considering the cost-effectiveness of new therapies or patient pathways, the incremental cost of care over the background population is an important measure. The value of our analyses lies in the detailed stratification of that incremental cost, which provides the economic context against with which to evaluate novel interventions for CAH. A comparison of healthcare costs in CAH with those in other inborn diseases falls outside the scope of this particular study but would merit future attention.
A limitation in our analysis of depression also arises from the nature of the data source: in the necessity of setting the CAH patients' index dates (and start of follow-up) as the later of their practice registration date and their first record of CAH. There is reason to believe that the distribution of diagnoses, including that of depression, may cluster around the registration period, when patient histories are taken and initial health checks carried out. The design of our comparative analysis only required that the matching reference patient be registered at the CAH patient's index date. Consequently, the periregistration period was less well captured in the control arm of the study, which would have led to ascertainment bias if the outcome of depression were defined as incident depression subsequent to index date. We were therefore obliged to define the depression outcome as the lifetime prevalence of that condition.
In our analysis of treatment adherence, days' supply was identified from prescriptions recorded as having been issued by the primary-care practice. We have no record of whether those prescriptions were filled at a pharmacy or whether any of the supplied medicine was taken by the patient; our estimates of adherence are therefore conservative.
In conclusion and taking into account the above limitations, this is to our knowledge the first analysis of the health burden of CAH using long-term routine healthcare records. The findings that rates of depression and all-cause mortality are higher in CAH patients tally with the findings of long-term registry studies, such as those carried out in Sweden (3), and, unsurprisingly, these are reflected in patients' higher utilisation of healthcare resources. Before the introduction of glucocorticoid therapy in the 1950s, patients with CAH rarely survived into middle age. Although glucocorticoid therapy revolutionised the prognosis of the disease, much as insulin therapy transformed the care of type 1 diabetes, there has been a period of stasis in the treatment of this disease. The findings from this and other long-term studies demonstrate that further advances in therapy for patients with CAH are required to improve patients' quality and duration of life.
